Todays RNS27 Mar 2019 13:06
Todays RNS
It is good to see a profit was made but a 'paper profit' due to it being based on releasing deferred revenue for which most of the cash has already been received.Progress is clearly being made but the 'Elephant in the room' is still that a fund raise will be required in order to extend the cash run way beyond January 2020 as detailed below.Until the funding issue is resolved I cannot see how the SP can significantly improve this year.
Extract from the Notes to the Accounts:
'The Group is evaluating various options to finance its cash needs through a combination of some, or all, of the following: equity offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organisations and patient advocacy groups, debt financings, and marketing, distribution or licensing arrangements. Whilst the Group believes that funds would be available in this manner before the end of January 2020, there can be no assurance that the Group will be able to generate funds, on terms acceptable to the Group, on a timely basis or at all, which would impact the Group’s ability to continue as a going concern. The failure of the Group to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Group’s business, results of operations and financial condition.'